Total Funding
81
77
Total FundingSeries A raised
Growth Score
3 pts
Heat Score
14 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
6042
ImpriMed provides AI-driven precision medicine services to oncologists and pharmaceutical companies
- Valerie Goodwin-Adams: Chief Commercial Officer
- Sungwon Lim: Co-Founder & CEO
About the Company
ImpriMed is a company that creates individualized drug response prediction technology to help veterinarians fight lymphoma. The company's technology provides precision medicine techniques that allow veterinary oncologists to find appropriate anticancer drugs by developing a patient-derived database for pet cancer treatment that can eventually
be translated into human cancer care, allowing doctors to decide on a final treatment regimen based on a data-driven prediction of response success in each individual patient's body.
Women Founded
